Page last updated: 2024-12-06
isodialuric acid
Description
Isodialuric acid is a tautomeric form of dialuric acid, a heterocyclic compound with the molecular formula C4H4N2O4. It exists in equilibrium with dialuric acid and is known for its antioxidant and reducing properties. Isodialuric acid can be synthesized through various methods, including the reduction of alloxan with sodium amalgam or zinc dust in acidic conditions. Its antioxidant activity stems from its ability to scavenge free radicals and reduce oxidative stress. The compound has also been studied for its potential therapeutic applications, such as its ability to inhibit the formation of advanced glycation end products (AGEs) and its potential anti-inflammatory effects. The study of isodialuric acid is driven by its interesting chemical properties, its biological activity, and its potential applications in various fields, including medicine, food chemistry, and materials science.'
isodialuric acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
5,6-dihydroxyuracil : A nucleobase analogue that is uracil substituted at positions 5 and 6 by hydroxy groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 67956 |
| CHEBI ID | 132197 |
| SCHEMBL ID | 48171 |
| MeSH ID | M0247003 |
Synonyms (16)
| Synonym |
|---|
| brn 0135130 |
| einecs 207-145-0 |
| isodialuric acid |
| 5,6-dihydroxypyrimidine-2,4(1h,3h)-dione |
| CHEBI:132197 |
| 5,6-dihydroxy-1,2,3,4-tetrahydropyrimidine-2,4-dione |
| 102636-37-3 |
| 5,6-dihydroxyuracil |
| 5,6-dihydroxy-1h-pyrimidine-2,4-dione |
| 5,6-dihydroxy-2,4(1h,3h)pyrimidinedione |
| 2,4(1h,3h)-pyrimidinedione, 5,6-dihydroxy- |
| 5,6-dihydroxy-2,4(1h,3h)-pyrimidinedione |
| 2,4,5,6-tetraoxypyrimidine |
| SCHEMBL48171 |
| Q1208512 |
| dialuricacid(100mgx5) |
Roles (1)
| Role | Description |
|---|
| Mycoplasma genitalium metabolite | Any bacterial metabolite produced during a metabolic reaction in Mycoplasma genitalium. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
| Class | Description |
|---|
| pyrimidone | A pyrimidine carrying one or more oxo substituents. |
| nucleobase analogue | A molecule that can substitute for a normal nucleobase in nucleic acids. |
| hydroxypyrimidine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.58
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.58 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.37 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |